Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones

British Journal of Ophthalmology

Volumn 92, Issue 6, 2008, Pages 848-851

  Yamada, M ^a   Yoshida, J ^a   Hatou, S ^a   Yoshida, T ^a   Minagawa, Y ^a  

^a NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN PARC; PROTEIN PARE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOSUFLOXACIN;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CHILD; CODON; CONJUNCTIVA; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MICROFLORA; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; WILD TYPE;

AZA COMPOUNDS; CONJUNCTIVA; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GENES, MDR; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NAPHTHYRIDINES; OFLOXACIN; QUINOLINES; QUINOLONES; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 45249101344     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2007.129858     Document Type: Article

References (22)

1. O'Brien TP. Bacterial keratitis. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea and external disease: clinical diagnosis and management. Volume II. St Louis: Mosby-Year Book, 1997:1139-90.
2. Graves A, Henry M, O'Brien TP, et al. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones. Cornea 2001;20:301-5.
3. O'Brien TP, Maquire MG, Fink NE, et al. Efficacy of ofloxacin versus cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 1995;113:1257-65.
4. Study Group of National Surveillance of Infectious Keratitis in Japan. National surveillance of infectious keratitis in Japan. Current status of isolates, patient background, and treatment. J Jpn Ophthalmol Soc 2006;110:961-72.
5. Frohlich SJ, deKaspar HM, Grabson T, et al. Bacterial keratitis in patients with and without contact lens anamnesis. Klin Monat Augenheilk 1999;214:211-6.
6. Bourcier T, Thomas F, Borderie V, et al. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol 2003;87:834-8.
7. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:1-17.
8. Sandvig KU, Dannevig L. Postoperative endophthalmitis: establishment and results of a national registry. J Cataract Refract Surg 2003;29:1273-80.
9. Neu HC. Microbiologic aspects of fluoroquinolones. Am J Ophthalmol 1991;112(Suppl 4):S15-24.
10. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol 1991;112(Suppl 4):S34-47.
11. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ophthalmology 1996;103:1854-62.
12. Chalita MG, Hüfling-Lima AN, Paranhos A, et al. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during period of 15 years. Am J Ophthalmol 2004;137:43- 51.
13. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis. Ophthalmology 1999;106:1313-8.
14. Kurokawa N, Hayashi K, Konishi M, et al. Increasing ofloxacin resistance of bacterial flora from conjunctival sac of preoperative ophthalmic patients in Japan. Jpn J Ophthalmol 2002;46:586-9.
15. Dubin DT, Fitzgibbon JE, Nahvi MD, et al. Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin. Antimicrob Agents Chemother 1999;43:1631-7.
16. Li Z, Deguchi T, Yasuda M, et al. Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis. Antimicrob Agents Chemother 1998;42:3293-5.
17. Sreedharan S, Peterson LR, Fisher LM. Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother 1991;35:2151-4.
18. Wang T, Tanaka M, Sato K. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob Agents Chemother 1998;42:23-40.
19. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002;2:530-8.
20. Horii T, Suzuki Y, Monji A, et al. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effect of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis 2003;46:139-45.
21. Iihara H, Suzuki T, Kawamura Y, et al. Emerging multiple mutations and high-level fluoroquinolone resistance in methicillin-resistant Staphylococcus aureus isolated from ocular infections. Diagn Microbiol Infect Dis 2006;56:297-303.
22. Japanese Society of Chemotherapy. Revision of methods for determining minimum inhibitory concentrations. Chemotherapy 1981;29:76-9.